Navigation Links
iCo Therapeutics Closes $1.3 Million Private Placement
Date:2/9/2009

acement. All securities issued in the private placement are subject to a four month hold period. The private placement is subject to regulatory approval, including the approval of the TSX Venture Exchange.

About iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products, iCo-007, in Phase I for the treatment of Diabetic Macular Edema, iCo-008, a product with Phase II clinical history to be developed for severe ocular allergies, and iCo-009, an oral formulation of Amphotericin B for sight and life - threatening diseases. iCo-009 also represents a new drug delivery technology with the potential to reprofile other parenteral administered drugs to the oral route of administration. iCo Therapeutics trades on the TSX-Venture exchange under the symbol "ICO". For more information, visit the company website at: www.icotherapeutics.com

    No regulatory authority has approved or disapproved the content of this
    release. The TSX Venture Exchange does not accept responsibility for the
    adequacy or accuracy of this release.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics' current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial per
'/>"/>

SOURCE iCo Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
2. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
3. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
4. Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share
5. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
6. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
7. Omnitura Therapeutics Announces Private Placement Financing
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. Cell Therapeutics Receives Additional NASDAQ Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... that use light, rather than electricity, to move ... energy efficiency is a growing concern as chips, ... components of optical circuits light emitters, modulators, ... build. One promising light source for optical chips ... properties when deposited as a single, atom-thick layer. ...
(Date:9/19/2014)... SPRINGS, Florida , September 19, 2014 ... in medical technology, development of emerging drug systems and ... PBIO), Benton, Dickinson and Company (NYSE: BDX ... ), Regado Biosciences Inc. (NASDAQ: RGDO ), ... Hologic Inc. (NASDAQ: HOLX) Pressure BioSciences, Inc. ...
(Date:9/19/2014)... BioTech News Coverage: Progress made ... of studies and trials.  Companies in focus are: GenSpera ... LLY ), Gilead Sciences Inc. (NASDAQ: ... and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, ... for the treatment of cancer, announced that the United ...
(Date:9/19/2014)... Dublin ... announced the addition of the  "Micro Market Monitor ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... fastest-growing segments in the chromatography market. The market ... expected to reach $2.0 billion by 2019, at ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7Micro Market Monitor : Global Pre-packed Chromatography Columns 2
... VANCOUVER , July 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ... quarter ended June 30, 2010 . , ... "We are pleased to report continued quarter over quarter ... Products," said Dr. William Hunter , President and CEO of Angiotech. ...
... lend materials new characteristics are generally complicated and therefore ... to astonishment when scientists report on new methods which ... they use economically priced starting materials but also do ... framework made of polystyrene This is exactly ...
... Inc. (Nasdaq: MYL ) today announced that it intends to ... senior notes through a reopening of its Senior Notes due 2020, ... as additional notes under an existing indenture under which Mylan issued ... 2020 on May 19, 2010 . The notes to be ...
Cached Biology Technology:Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 2Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 3Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 4Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 5Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 6Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 7Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 8Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 9Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 10Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 11Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 12Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 13Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 14Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 15Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 16Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 17Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 18Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 19Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 20Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 21Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 22Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 23Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 24Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 25Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 26Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 27Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 28Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 29Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 30Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 31Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 32Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 33Empa grows 'sea urchin'-shaped structures 2Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020 2Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020 3
(Date:9/18/2014)... deep in the primitive brainstem has revealed how we ... School of Medicine and the University at Buffalo School ... second "sleep node" identified in the mammalian brain whose ... produce deep sleep. , Published online in August in ... half of all of the brain,s sleep-promoting activity originates ...
(Date:9/18/2014)... Space Station ever starts a "frequent flyers" program, fruit ... the orbiting laboratory has hosted increasing numbers of fruit ... the space station in April, and another is scheduled ... is planned to launch in December. , Fruit flies ... world-- and in space. Model organisms can reveal the ...
(Date:9/18/2014)... their colleagues have built the first smartphone app ... and behavioral trends. In other words, your smartphone ... you don,t -- and how that affects you. ... stress, depression and loneliness to their academic performance, ... for example, to monitor mental health, trigger ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4
... , This news release is available in ... songbirds learn their songs from an adult model, mostly from the ... these songs are copied. Researchers from the Max Planck Institute for ... mechanism that is responsible for the differences in the intensity of ...
... Increasing awareness of biometrics across industries will spur ... adoption of biometrics has been concentrated in the ... for applications such as ATMs, retail points of ... have undergone substantial advancements and are gaining prominence, ...
... scientists are working to determine how neurons are generated, ... like Tuberous Sclerosis Complex (TSC). TSC is a ... in the brain and other vital organs and may ... that may arise from the abnormal generation of neurons. ...
Cached Biology News:Super song learners 2Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 2Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 3Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 4Clemson University study points to possible treatment for brain disorders 2
... Baculovirus Expression System with Gateway™ Technology ... plasmids containing the polyhedrin promoter. The ... baculovirus genome (bacmid DNA) by site-specific ... cells. The recombinant bacmid DNA is ...
Request Info...
...
...
Biology Products: